FDA

Exclusive Nicholas Florko

STAT Plus: Top FDA officials weighing regulation of ultra-processed foods, internal documents show

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

In the Lab Alia Sajani and Angus Chen

CAR-T cell therapy’s complications, as well as its benefits, become clearer in ‘flurry’ of cancer studies

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

The Readout Elaine Chen

STAT Plus: uniQure shares soar on Huntington’s data

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

First Opinion Lynn Brielmaier

My stalled relay race to get access to ALS drugs in development

Exclusive Brittany Trang and Mohana Ravindranath

STAT Plus: Top Biden administration officials withdraw from Coalition for Health AI

Politics Associated Press

STAT Plus: Supreme Court to weigh whether the FDA was heavy-handed with flavored e-cigarette products

Matt's Take Matthew Herper

STAT Plus: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes

Pharma Nicholas Florko, Lizzy Lawrence, John Wilkerson, and Elaine Chen

STAT Plus: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry

Letters to the editor Patrick Skerrett

What readers have to say about long Covid, FDA and diversity, and more

Politics Nicholas Florko

STAT Plus: Vape makers see Supreme Court ruling as a weapon in fighting FDA

The Readout Meghana Keshavan

STAT Plus: Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?

Politics Olivia Goldhill

STAT Plus: Don’t write off MDMA yet: How the FDA got on board with psychedelics

The Readout Elaine Chen

STAT Plus: Exclusive: European VC Forbion hires Dyne CEO, expands in US

Biotech John Wilkerson

STAT Plus: FDA issues long-awaited draft guidance for enrolling more people of color in clinical trials

The Readout Elaine Chen

STAT Plus: Intellia says its CRISPR-based therapy can be redosed

First Opinion Tamei Elliott and Maria Vassileva

FDA: Don’t rush publishing your diversity guidance plan. Take your time and do it right

The Readout Elaine Chen

STAT Plus: One firm, two conflicting takes on Alnylam’s HELIOS-B 

First Opinion Andrew D. Forsyth, Mallory O. Johnson, and Jae M. Sevelius

Turning a ‘no’ vote into progress: How to advance MDMA-assisted psychotherapy for PTSD

The Readout Meghana Keshavan

STAT Plus: The findings from Alnylam’s highly anticipated readout  

First Opinion Mark H. Smith

The FDA needs to embrace phage therapy to help fight antimicrobial resistance

Health Elizabeth Cooney

‘We’re failing right now’ in type 2 diabetes, FDA chief says

Biotech Adam Feuerstein

STAT Plus: What the Sarepta decision means for Duchenne patients, the company, and the FDA

Biotech Jason Mast and Matthew Herper

STAT Plus: Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy

Biotech Jason Mast

STAT Plus: FDA approves Sarepta’s Duchenne gene therapy for nearly all patients

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more